NVO Stock Risk & Deep Value Analysis
Novo Nordisk A/S
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About NVO Stock
We analyzed Novo Nordisk A/S using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran NVO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
NVO Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is sustained and aggressive competition from Eli Lilly and other emerging players in the GLP-1 market, which could continue to pressure realized prices. As evidenced by the Q1 2026 report, a 4% decline in adjusted sales due to pricing and a 6% decline in adjusted operating profit could persist, leading to continued margin erosion and a slower growth trajectory, making even modest earnings growth challenging.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Adjusted sales decline of 4% YoY in Q1 2026 due to lower realized prices, despite strong reported growth.
- ⚠
Adjusted operating profit decline of 6% YoY in Q1 2026, indicating margin compression.
- ⚠
Reliance on the GLP-1 franchise for a significant portion of revenue, making it vulnerable to competitive and pricing pressures.
- ⚠
Market capitalization ($1.3T) makes 10x growth ($13T) in 3-5 years practically impossible.
Upcoming Risk Events
- 📅
Eli Lilly's competitive advancements (ongoing through 2026-2027): Continued strong sales performance of Zepbound/Mounjaro and potential new products could further erode Novo Nordisk's market share and pricing power, impacting adjusted sales growth.
- 📅
Increased regulatory scrutiny on drug pricing (Q4 2026 onwards): New legislation or payer pressure in the U.S. or Europe could lead to further declines in realized prices for GLP-1 drugs, negatively impacting profitability beyond the Q1 2026 adjusted decline.
When to Reconsider
- 🚪
Exit if quarterly adjusted operating profit declines for a second consecutive quarter, signaling persistent margin erosion.
- 🚪
Sell if Novo Nordisk's market share in branded obesity drugs drops below 60% for two consecutive quarters due to competitor gains.
- 🚪
Exit if 2027 guidance for sales growth (at CER) is less than 10%, indicating significant slowdown.
Unlock NVO Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Novo Nordisk A/S (NVO) Do?
Market Cap
$1.29T
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
78,554
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit Novo Nordisk A/S WebsiteInvestment Thesis
If Novo Nordisk successfully defends its market leadership in the rapidly expanding GLP-1 and obesity markets through continuous innovation, expanded indications, and strategic pricing, then it can sustain double-digit reported revenue growth and gradually improve adjusted profitability, supporting modest share price appreciation. This is bullish for long-term holders seeking stable growth, but it's not a 10x opportunity as the market is already pricing in significant success.
Is NVO Stock Undervalued?
Unlock the full AI analysis for NVO
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
NVO Price Targets & Strategy
12-Month Target
$52.00
Bull Case
$58.00
Bear Case
$40.00
Valuation Basis
Based on a 30x forward P/E applied to estimated FY26 EPS of $1.73 (assuming modest growth from current levels, tempered by adjusted profit declines).
Entry Strategy
Consider dollar-cost averaging in the $43-$46 range, particularly if the stock retests recent support levels, acknowledging limited 10x upside.
Exit Strategy
Take profit at $55+ if the stock rallies, with a stop-loss at $40 to protect against further downside from competitive pressures or unexpected pipeline setbacks.
Portfolio Allocation
1-2% for conservative investors seeking stability in a large-cap healthcare company, but not suitable for aggressive growth portfolios targeting 10x returns.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is NVO Financially Healthy?
Valuation
P/E Ratio
10.57
Forward P/E
11.87
EV/EBITDA
7.71
PEG Ratio
0.92
Price/Book
6.35
Price/Sales
3.57
Profitability
Gross Margin
81.85%
Operating Margin
45.30%
Net Margin
37.20%
Return on Equity
66.36%
Revenue Growth
8.13%
EPS
$27.41
Balance Sheet
Current Ratio
0.80
Quick Ratio
0.57
Debt/Equity
0.67
Total Debt
$20.59B
Cash & Equivalents
$4.24B
Cash Flow
Operating Cash Flow
$18.72B
Free Cash Flow
$9.01B
EBITDA
$147.45B
Other
Beta (Volatility)
1.85
Dividend Yield
3.99%
Does NVO Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable, but facing erosion pressure
Moat Sources
3 Identified
Novo Nordisk's moat is durable due to the high regulatory hurdles, extensive R&D required for drug development, and established patient/physician trust. However, highly innovative and well-capitalized competitors like Eli Lilly pose a significant threat to its pricing power and market share.
Moat Erosion Risks
- •Development of superior or equally effective GLP-1 or next-generation obesity drugs by competitors, eroding NVO's market leadership and pricing power.
- •Expiration of key patents for its blockbuster drugs, leading to generic competition and significant revenue loss if not offset by new pipeline successes.
NVO Competitive Moat Analysis
Sign up to see competitive advantages
NVO Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. While there's excitement around GLP-1s, competitive concerns temper overall retail enthusiasm.
Institutional Sentiment
Neutral. While NVO is a core institutional holding, the intense competition and recent adjusted profit decline likely lead to a cautious outlook from analysts, even with a raised outlook.
Insider Activity (Form 4)
No Form 4 insider transactions were present in the supplied search results for the last 90 days. Therefore, no verifiable insider buys/sells or dollar values can be stated.
Options Flow
Normal options activity. No specific unusual options activity or significant put/call ratio skew was present in the supplied search results.
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
Historically, Novo Nordisk tends to react positively to strong reported sales and guidance raises, but concerns over competitive landscape and pricing have led to tempered responses even on beats.
Key Metrics to Watch
Competitive Position
Top Competitor
LLY
Market Share Trend
Gaining market share in branded obesity due to strong demand and product launches, but facing significant competitive pressure from Eli Lilly's GLP-1 offerings, particularly concerning realized prices.
Valuation vs Peers
Trading at a premium to many pharmaceutical peers due to its dominant position in high-growth GLP-1 markets, but this premium is under pressure from competitive forces. Not valued for 10x growth.
Competitive Advantages
- •Strong intellectual property and patent portfolio for GLP-1 agonists.
- •Massive manufacturing scale and global distribution network.
- •Established brand recognition and deep R&D expertise in metabolic and rare diseases.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive NVO Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (estimated early August 2026): If oral Wegovy uptake exceeds internal forecasts and adjusted operating profit stabilizes, it could signal easing pricing pressure.
- •Regulatory updates on new indications for GLP-1 products (Q3-Q4 2026): Positive outcomes, particularly for cardiovascular benefits or broader metabolic applications, could expand TAM.
Medium-Term (6-18 months)
- •Expansion of GLP-1 product reimbursement coverage in key international markets (2027-2028): Success in expanding to high-growth regions like China could add $1B+ to annual revenue.
- •Advancement of novel pipeline assets beyond GLP-1 (e.g., rare disease, next-gen obesity treatments) to Phase 3 trials (2027): Successful trial progression could diversify revenue by $500M+ annually in 5 years.
Long-Term (18+ months)
- •Sustained leadership in chronic disease management through AI and digital health integration (beyond 2028): If NVO successfully leverages AI for personalized medicine and patient adherence, it could expand market reach and improve treatment outcomes, driving sustained, albeit not 10x, growth.
- •Successful development and commercialization of a multi-modal obesity treatment (beyond 2028): If NVO launches a superior combination therapy, it could further solidify market share and expand into new patient segments, potentially adding several billions to annual revenue.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for NVO?
- ✓
Watch quarterly adjusted operating profit trends; sustained declines (beyond Q1 2026's -6%) would signal persistent competitive pressure.
- ✓
Monitor global GLP-1 market share data for any significant erosion to competitors like Eli Lilly, particularly in key U.S. and European markets.
- ✓
Track regulatory approvals and commercialization progress for new pipeline assets beyond current GLP-1 applications; successful diversification is key to long-term stability.
Bull Case Analysis
Sign up free to see the bull case
Competing with NVO
See how Novo Nordisk A/S compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Novo Nordisk A/S NVO | $1.3T | 1.3 | 10.6 | $48.6B | 37.2% | 8.1% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Novo Nordisk A/S Makes Money
Novo Nordisk is a global pharmaceutical company primarily focused on discovering, developing, manufacturing, and marketing pharmaceutical products. Its core business revolves around treatments for diabetes, including various types of insulin and GLP-1 receptor agonists, and more recently, obesity management with drugs like Wegovy. They also have a smaller segment in rare blood and endocrine disorders. The company generates revenue by selling these prescription medicines to patients globally through healthcare providers and pharmacies, often with reimbursement from health insurance plans.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Novo Nordisk A/S (NVO)?
As of May 29, 2026, Novo Nordisk A/S has a DVR Score of 1.3 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Novo Nordisk A/S?
Novo Nordisk A/S's market capitalization is approximately $1.3T. The company operates in the Healthcare sector within the Drug Manufacturers - General industry.
What ticker symbol does Novo Nordisk A/S use?
NVO is the ticker symbol for Novo Nordisk A/S. The company trades on the NYQ.
What is the risk level for NVO stock?
Our analysis rates Novo Nordisk A/S's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of NVO?
Novo Nordisk A/S currently has a price-to-earnings (P/E) ratio of 10.6. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Does Novo Nordisk A/S pay a dividend?
Yes, Novo Nordisk A/S pays a dividend with a current yield of approximately 3.99%.
Is Novo Nordisk A/S's revenue growing?
Novo Nordisk A/S has reported revenue growth of 8.1%. The company is growing at a moderate pace.
Is NVO stock profitable?
Novo Nordisk A/S has a profit margin of 37.2%. This indicates strong profitability.
How often is the NVO DVR analysis updated?
Our AI-powered analysis of Novo Nordisk A/S is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 29, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for NVO (Novo Nordisk A/S) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.